Your browser is no longer supported. Please, upgrade your browser.
CTMX CytomX Therapeutics, Inc. monthly Stock Chart
CTMX [NASD]
CytomX Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.67 Insider Own0.20% Shs Outstand45.72M Perf Week-10.95%
Market Cap364.26M Forward P/E- EPS next Y-2.73 Insider Trans-28.46% Shs Float41.54M Perf Month-30.12%
Income-75.90M PEG- EPS next Q-0.08 Inst Own80.20% Short Float2.83% Perf Quarter11.34%
Sales77.60M P/S4.69 EPS this Y-11.10% Inst Trans-0.16% Short Ratio1.80 Perf Half Y33.94%
Book/sh1.53 P/B5.26 EPS next Y-11.10% ROA-19.50% Target Price13.30 Perf Year-22.82%
Cash/sh5.48 P/C1.47 EPS next 5Y-0.90% ROE-99.70% 52W Range3.60 - 15.44 Perf YTD-3.13%
Dividend- P/FCF- EPS past 5Y-17.70% ROI-216.20% 52W High-47.86% Beta0.71
Dividend %- Quick Ratio3.80 Sales past 5Y62.50% Gross Margin- 52W Low123.92% ATR0.90
Employees158 Current Ratio3.80 Sales Q/Q68.10% Oper. Margin- RSI (14)37.93 Volatility6.45% 8.34%
OptionableYes Debt/Eq0.00 EPS Q/Q185.30% Profit Margin-97.80% Rel Volume0.92 Prev Close8.12
ShortableYes LT Debt/Eq0.00 EarningsMay 07 AMC Payout- Avg Volume652.06K Price8.05
Recom1.90 SMA20-23.50% SMA50-13.49% SMA2003.28% Volume602,919 Change-0.86%
Jun-01-20Downgrade Jefferies Buy → Hold $16 → $10
May-14-20Reiterated H.C. Wainwright Buy $16 → $12
Mar-24-20Upgrade Wedbush Neutral → Outperform
Mar-04-20Initiated Barclays Equal Weight $7
Nov-20-19Initiated Guggenheim Buy
Nov-11-19Downgrade Wedbush Outperform → Neutral $25 → $8
Jun-13-19Initiated Mizuho Buy
May-14-19Initiated Cantor Fitzgerald Overweight $21
Mar-11-19Initiated Barclays Overweight $16
Nov-26-18Initiated Piper Jaffray Overweight $22
Oct-15-18Initiated Goldman Neutral $21
Sep-13-18Initiated H.C. Wainwright Buy $32
Jun-01-18Initiated SunTrust Buy $38
Jan-05-18Initiated Citigroup Buy $40
Sep-08-17Initiated Wedbush Outperform $26
Mar-27-17Initiated H.C. Wainwright Buy $24
Mar-02-17Initiated Instinet Buy $21
Jan-03-17Downgrade Oppenheimer Outperform → Perform
Nov-02-15Initiated Oppenheimer Outperform $17
Nov-02-15Initiated Jefferies Buy $19
Jun-03-20 06:00PM  
05:50PM  
05:03PM  
01:35PM  
01:30PM  
01:00PM  
Jun-02-20 11:10AM  
Jun-01-20 11:35PM  
05:52PM  
04:45PM  
02:50PM  
01:43PM  
11:00AM  
10:27AM  
10:21AM  
09:46AM  
06:20AM  
May-30-20 03:30PM  
May-29-20 03:59PM  
03:00PM  
08:02AM  
May-28-20 05:56PM  
04:55PM  
04:05PM  
03:50PM  
02:00PM  
01:35PM  
01:00PM  
May-27-20 08:21PM  
07:00PM  
07:00PM  
07:00PM  
06:12PM  
04:25PM  
03:10PM  
03:10PM  
02:00PM  
01:40PM  
12:46PM  
11:45AM  
11:00AM  
10:20AM  
09:22AM  
May-26-20 08:00PM  
07:00PM  
06:49PM  
04:55PM  
04:22PM  
03:10PM  
02:15PM  
01:45PM  
01:13PM  
09:45AM  
09:18AM  
08:00AM  
May-25-20 03:49PM  
02:45PM  
07:45AM  
06:20AM  
May-24-20 07:35PM  
02:35PM  
01:00PM  
May-23-20 07:44PM  
02:30PM  
09:37AM  
May-22-20 06:15PM  
05:24PM  
03:45PM  
03:00PM  
03:00PM  
02:55PM  
02:12PM  
11:00AM  
10:23AM  
09:19AM  
May-21-20 05:48PM  
05:29PM  
01:15PM  
May-20-20 09:41AM  
May-19-20 12:40PM  
May-15-20 11:34AM  
May-14-20 02:35PM  
May-13-20 05:19PM  
May-10-20 09:04AM  
May-09-20 08:50AM  
May-08-20 07:33PM  
02:30PM  
May-07-20 07:14PM  
04:10PM  
12:00PM  
May-05-20 08:00AM  
May-04-20 08:11AM  
Apr-30-20 12:34PM  
Apr-29-20 04:05PM  
Apr-28-20 04:05PM  
Apr-27-20 08:00AM  
Apr-23-20 08:33AM  
Apr-22-20 12:00PM  
Apr-17-20 10:23AM  
Apr-09-20 06:08PM  
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 immuno-oncology target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel drug target; BMS-986249, a CTLA-4 Probody therapeutic drug; CX-2029, a PDC targeting CD71; and CX-188, a Probody therapeutic targeting PD-1 anti-cancer target. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., and Pfizer Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
McCarthy Sean A.President and CEOMay 12Option Exercise1.1336,00040,820120,306May 14 04:31 PM
McCarthy Sean A.President and CEOMay 12Sale15.0036,000540,00084,306May 14 04:31 PM